DE60216471D1 - Pharmazeutische zubereitungen mit einem cortisol synthese inhibitor - Google Patents

Pharmazeutische zubereitungen mit einem cortisol synthese inhibitor

Info

Publication number
DE60216471D1
DE60216471D1 DE60216471T DE60216471T DE60216471D1 DE 60216471 D1 DE60216471 D1 DE 60216471D1 DE 60216471 T DE60216471 T DE 60216471T DE 60216471 T DE60216471 T DE 60216471T DE 60216471 D1 DE60216471 D1 DE 60216471D1
Authority
DE
Germany
Prior art keywords
melting point
lipid
pharmaceutical preparations
synthesis inhibitor
excipients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60216471T
Other languages
English (en)
Other versions
DE60216471T2 (de
Inventor
Helena Ljusberg
Veronica Hylen
Helen Fyge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortendo AB
Original Assignee
Cortendo AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo AB filed Critical Cortendo AB
Publication of DE60216471D1 publication Critical patent/DE60216471D1/de
Application granted granted Critical
Publication of DE60216471T2 publication Critical patent/DE60216471T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60216471T 2001-07-26 2002-07-26 Pharmazeutische zubereitungen mit einem cortisol synthese inhibitor Expired - Lifetime DE60216471T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0118300 2001-07-26
GBGB0118300.3A GB0118300D0 (en) 2001-07-26 2001-07-26 Formulations
PCT/GB2002/003444 WO2003011258A1 (en) 2001-07-26 2002-07-26 Pharmaceutical formulations comprising ketoconazole

Publications (2)

Publication Number Publication Date
DE60216471D1 true DE60216471D1 (de) 2007-01-11
DE60216471T2 DE60216471T2 (de) 2007-03-29

Family

ID=9919282

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60216471T Expired - Lifetime DE60216471T2 (de) 2001-07-26 2002-07-26 Pharmazeutische zubereitungen mit einem cortisol synthese inhibitor

Country Status (6)

Country Link
US (1) US20050013834A1 (de)
EP (1) EP1414419B1 (de)
AT (1) ATE346592T1 (de)
DE (1) DE60216471T2 (de)
GB (1) GB0118300D0 (de)
WO (1) WO2003011258A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
ES2346961T3 (es) 2001-11-22 2010-10-22 Biovitrum Ab Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
MX2007008331A (es) * 2005-01-10 2008-01-14 Cortendo Invest Ab Publ Metodos y composiciones para el tratamiento de diabetes, sindrome metabolico y otras condiciones.
AU2007204969A1 (en) * 2006-01-10 2007-07-19 Cortendo Invest Ab Methods and compositions for treating prostate cancer
AU2007237899A1 (en) * 2006-04-18 2007-10-25 Cortendo Invest, Ab Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
BRPI0719835A2 (pt) 2006-10-02 2014-05-06 Cortendo Invest Ab Enantiômero de cetoconazol em humanos
CN101686994B (zh) * 2006-10-20 2013-05-01 陶氏环球技术公司 水溶性纤维素衍生物制备用于预防或治疗代谢综合征的药物等的用途
AR082803A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
WO2015048311A1 (en) * 2013-09-25 2015-04-02 Cortendo Ab (Publ) Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibitng cytochrome p450 inhibition
US11324699B2 (en) * 2014-12-04 2022-05-10 Capsugel Belgium Nv Lipid multiparticulate formulations
EP3863634A1 (de) 2018-10-12 2021-08-18 Strongbridge Dublin Limited Levoketoconazol zur behandlung von kongenitaler adrenalhyperplasie und primärem aldosteronismus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
EP0643620B1 (de) * 1991-10-04 1999-07-21 Gs Development Ab Teilchen, methode zur herstellung der teilchen und deren verwendung
AU5955094A (en) * 1992-12-22 1994-07-19 Sepracor, Inc. Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
JP3081766B2 (ja) * 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
EP0779810B8 (de) * 1994-08-09 2003-09-17 Cortendo AB Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
US6428809B1 (en) * 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions

Also Published As

Publication number Publication date
WO2003011258A1 (en) 2003-02-13
EP1414419B1 (de) 2006-11-29
ATE346592T1 (de) 2006-12-15
EP1414419A1 (de) 2004-05-06
US20050013834A1 (en) 2005-01-20
DE60216471T2 (de) 2007-03-29
GB0118300D0 (en) 2001-09-19

Similar Documents

Publication Publication Date Title
GEP20043180B (en) Polymorphous Crystal Forms of Celecoxib, Methods for Their Production and Pharmaceutical Composition Comprising the Same for Treatment or Prevention of Diseases Caused by Cyclooxygenase-2
DE60305724D1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
AR055916A1 (es) Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica
BRPI0410219A (pt) composições farmacêuticas de vareniclina
DE60216471D1 (de) Pharmazeutische zubereitungen mit einem cortisol synthese inhibitor
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
RS50025B (sr) Farmaceutski preparati koji mogu da budu gelirani
BR0314898A (pt) Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
DE60231298D1 (de) Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
BR0108395A (pt) Derivados de pirrolopirimidinona, processos de preparação e uso
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
CY1106542T1 (el) Μεθοδος για παρασκευη φαρμακευτικων συνθεσεων για χρηση με συνταγοποιησεις μαλακης ζελατινης
MEP56908A (en) Reconstitutable parenteral composition containing a cox-2 inhibitor
GEP20043237B (en) Pyrazoline Derivatives, Method for Their Preparation and Compositions Containing Them for Treatment of Diseases Mediated by Cyclooxygenase-2
IL172602A0 (en) Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]- octane-3-carboxylic acid deriv atives
ATE386725T1 (de) Heterocyclylverbindungen
SE9904413D0 (sv) Comminuted form
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DK1305057T3 (da) Mikropartikelformig biomaterialesammensætning af hyaluronsyre til medicinsk anvendelse
IL163608A (en) Sulfonanilides are conserved in their amino / amino acids and derivatives, their process, their pharmaceutical preparations, and their conjugated antibodies and their use in the preparation of drugs for the treatment of culture disorders
DE69813263D1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
JP7086597B2 (ja) 外用組成物

Legal Events

Date Code Title Description
8364 No opposition during term of opposition